» Articles » PMID: 28710314

Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

Abstract

Sarcomatoid renal cell carcinoma (SRCC) ranks among the most aggressive clinicopathologic phenotypes of RCC. However, the paucity of high-quality, genome-wide molecular examinations of SRCC has hindered our understanding of this entity. We interrogated the mutational, copy number, and transcriptional characteristics of SRCC and compared these data with those of nonsarcomatoid RCC (RCC). We evaluated whole-exome sequencing, single-nucleotide polymorphism, and RNA sequencing data from patients with SRCC ( = 65) and RCC ( = 598) across different parent RCC subtypes, including clear-cell RCC, papillary RCC, and chromophobe RCC subtypes. SRCC was molecularly discrete from RCC and clustered according to its parent RCC subtype, though with upregulation of TGFβ signaling across all subtypes. The epithelioid (E-) and spindled (S-) histologic components of SRCC did not show differences in mutational load among cancer-related genes despite a higher mutational burden in S-. Notably, sarcomatoid clear-cell RCC (SccRCC) showed significantly fewer deletions at 3p21-25, a lower rate of two-hit loss for and , and more mutations in , , and compared with ccRCC. A two-hit loss involving predicted for ccRCC and a better prognosis, whereas mutations in , , or predicted for SccRCC and worse prognosis. SRCC segregates by parent subtype, and SccRCC has a fundamentally different early molecular pathogenesis, usually lacking the classic 3p21-25 deletion and showing distinctive mutational and transcriptional profiles. These features prompt a more precise molecular classification of RCC, with diagnostic, prognostic, and therapeutic implications. .

Citing Articles

Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment.

Soupir A, Hayes M, Peak T, Ospina O, Chakiryan N, Berglund A Genome Biol. 2024; 25(1):308.

PMID: 39639369 PMC: 11622564. DOI: 10.1186/s13059-024-03435-z.


Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation (osteosarcomatous and chondrosarcomatous differentiation)-A Case Report and Comprehensive Review.

Rao M, G A, Navriya S, Sureka B, Kudunthail J J Kidney Cancer VHL. 2024; 11(3):59-64.

PMID: 39280927 PMC: 11397982. DOI: 10.15586/jkcvhl.v11i3.343.


Genetic study of the and genes in renal cell carcinoma patients.

Kiatprungvech N, Sangkum P, Malinee R, Sommaluan S, Korkiatsakul V, Worawichawong S Pract Lab Med. 2024; 40:e00410.

PMID: 38867760 PMC: 11167386. DOI: 10.1016/j.plabm.2024.e00410.


Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma.

Kapur P, Zhong H, Le D, Mukhopadhyay R, Miyata J, Carrillo D JCI Insight. 2024; 9(10).

PMID: 38775158 PMC: 11141915. DOI: 10.1172/jci.insight.176743.


Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.

Tu S, Trikannad A, Vellanki S, Hussain M, Malik N, Singh S Cancers (Basel). 2024; 16(6).

PMID: 38539487 PMC: 10969562. DOI: 10.3390/cancers16061151.


References
1.
Sircar K, Yoo S, Majewski T, Wani K, Patel L, Voicu H . Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas. J Pathol Clin Res. 2016; 1(4):212-24. PMC: 4939892. DOI: 10.1002/cjp2.23. View

2.
Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

3.
Davis C, Ricketts C, Wang M, Yang L, Cherniack A, Shen H . The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014; 26(3):319-330. PMC: 4160352. DOI: 10.1016/j.ccr.2014.07.014. View

4.
Klatte T, Rao P, de Martino M, LaRochelle J, Shuch B, Zomorodian N . Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009; 27(5):746-53. DOI: 10.1200/JCO.2007.15.8345. View

5.
Patard J, Fergelot P, Karakiewicz P, Klatte T, Trinh Q, Rioux-Leclercq N . Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008; 123(2):395-400. PMC: 2721857. DOI: 10.1002/ijc.23496. View